Brief: Nurexone Biologic Extends Spinal Cord Injury Therapy Portfolio With New Rna Sequences Promoting Healing And Regeneration
29/11/2023 15:58
Nurexone Biologic Inc NRX.V :
* NUREXONE BIOLOGIC EXTENDS SPINAL CORD INJURY THERAPY
PORTFOLIO
WITH NEW RNA SEQUENCES PROMOTING HEALING AND REGENERATION
Source text for Eikon: ID:nGNX9NHFG4
Further company coverage: NRX.V
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement